Royal Bank of Canada
IDNA icon

Royal Bank of Canada’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Royal Bank of Canada’s Portfolio IDNA Stock Details IDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.51M Sell
51,853
-9,002
-15% -$261K ﹤0.01% 3306
2025
Q4 		$1.59M Sell
60,855
-10,229
-14% -$263K ﹤0.01% 3292
2025
Q3 		$1.68M Sell
71,084
-3,017
-4% -$66.7K ﹤0.01% 3548
2025
Q2 		$1.52M Buy
74,101
+627
+0.9% +$12.6K ﹤0.01% 3533
2025
Q1 		$1.51M Sell
73,474
-542
-0.7% -$12.1K ﹤0.01% 3168
2024
Q4 		$1.68M Buy
74,016
+4,722
+7% +$113K ﹤0.01% 3136
2024
Q3 		$1.71M Sell
69,294
-2,918
-4% -$71.1K ﹤0.01% 3106
2024
Q2 		$1.67M Sell
72,212
-874
-1% -$20.5K ﹤0.01% 3038
2024
Q1 		$1.76M Sell
73,086
-622
-0.8% -$14.6K ﹤0.01% 3026
2023
Q4 		$1.7M Buy
73,708
+3,789
+5% +$76.1K ﹤0.01% 3200
2023
Q3 		$1.42M Buy
69,919
+5,950
+9% +$134K ﹤0.01% 3136
2023
Q2 		$1.49M Buy
63,969
+3,574
+6% +$85.7K ﹤0.01% 3063
2023
Q1 		$1.41M Buy
60,395
+1,156
+2% +$28.9K ﹤0.01% 3080
2022
Q4 		$1.49M Sell
59,239
-3,111
-5% -$83.6K ﹤0.01% 3158
2022
Q3 		$1.65M Sell
62,350
-3,465
-5% -$107K ﹤0.01% 3018
2022
Q2 		$1.9M Sell
65,815
-27,841
-30% -$831K ﹤0.01% 2936
2022
Q1 		$3.23M Buy
93,656
+13,263
+16% +$469K ﹤0.01% 2616
2021
Q4 		$3.52M Buy
80,393
+29,557
+58% +$1.4M ﹤0.01% 2652
2021
Q3 		$2.58M Sell
50,836
-49,655
-49% -$2.59M ﹤0.01% 2862
2021
Q2 		$5.23M Buy
100,491
+7,589
+8% +$356K ﹤0.01% 2289
2021
Q1 		$4.25M Buy
92,902
+24,170
+35% +$1.18M ﹤0.01% 2367
2020
Q4 		$3.16M Sell
68,732
-15,679
-19% -$677K ﹤0.01% 2534
2020
Q3 		$3.29M Buy
84,411
+14,435
+21% +$555K ﹤0.01% 2297
2020
Q2 		$2.66M Buy
69,976
+27,336
+64% +$923K ﹤0.01% 2403
2020
Q1 		$1.15M Buy
+42,640
New +$1.21M ﹤0.01% 2921

Other funds holding IDNA

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

Royal Bank of Canada's IDNA Position: Q1 2026 in Review

Royal Bank of Canada reduced its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 15% in Q1 2026, selling an estimated $261K and leaving 51,853 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3306.

Royal Bank of Canada first reported a position in IDNA in Q1 2020 and has held it in 25 quarters since. The position peaked at $5.23M in Q2 2021. 60 funds tracked by Wall St. Rank hold IDNA as of Q1 2026.

  • Royal Bank of Canada held 51,853 shares of iShares Genomics Immunology and Healthcare ETF worth $1.51M as of Q1 2026.
  • Royal Bank of Canada sold 9,002 iShares Genomics Immunology and Healthcare ETF shares in Q1 2026, an estimated $261K.
  • iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3306 holding.
  • Royal Bank of Canada first reported a position in iShares Genomics Immunology and Healthcare ETF in Q1 2020 and has held it in 25 quarters since.
  • Royal Bank of Canada's iShares Genomics Immunology and Healthcare ETF position peaked at $5.23M in Q2 2021.
  • 60 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.